Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt reported activity in April under its French law-governed liquidity agreement with Invest Securities, which is mandated to support trading liquidity in the company’s ordinary shares. During the month, the broker bought 33,019 shares and sold 14,884 shares within a narrow price range, leaving 145,061 shares held in treasury at the end of April.
The company confirmed that its total number of ordinary shares stands at 72,588,088, a key reference figure for investors monitoring ownership thresholds under French disclosure rules. Management also reiterated that shares acquired under the liquidity arrangement may be cancelled or retained as non-voting treasury stock, giving Novacyt flexibility in managing its capital structure and market liquidity.
More about Novacyt
Novacyt is an international molecular diagnostics company focused on delivering genomic medicine through a broad portfolio of integrated technologies and services. It develops, manufactures and commercialises molecular assays, instrumentation and end-to-end workflows for sectors including human and animal health and environmental testing, and operates globally from its French headquarters with offices in the UK, Singapore, the US and Canada.
The Group is organised into clinical diagnostics, instrumentation and research-use-only segments, covering reproductive health, precision medicine and infectious diseases, as well as DNA sample preparation platforms and qPCR instruments. Its recent acquisition of Southern Cross Diagnostics in Australia has expanded distribution channels into the life sciences and diagnostics markets across the Asia-Pacific region, underpinning its dual listing on AIM in London and Euronext Growth in Paris.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.